Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, Frederick W. Driscoll, Chief Financial Officer of Flexion Therapeutics, Inc., retired from his position effective March 31, 2017. Mr. Driscoll is continuing to provide services as a part-time, non-executive employee while the Company completes its on-going search for a new Chief Financial Officer.

Effective upon Mr. Driscoll’s retirement as Chief Financial Officer, Michael D. Clayman, M.D., the Company’s President and Chief Executive Officer, was appointed as the Company’s principal financial officer and principal accounting officer. Dr. Clayman’s biographical and compensation information is available in the Company’s prior filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed March 10, 2017, and its Definitive Proxy Statement, filed April 26, 2016.

About Flexion Therapeutics, Inc. (NASDAQ:FLXN)

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Recent Trading Information

Flexion Therapeutics, Inc. (NASDAQ:FLXN) closed its last trading session down -0.17 at 26.91 with 572,216 shares trading hands.